Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Pancreatic Cancer and Antibodies

Additional Information

Published Date Nov 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4418
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Pancreatic Cancer and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the compound strategy of Antibodies.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Pancreatic Cancer and Antibodies.

    To find out more about Triple Analysis: Lymphoma, Pancreatic Cancer and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Pancreatic Cancer and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
4SC
A&G Pharmaceutical
AB Science
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Alfacell
Algeta
Allos Therapeutics
ALSP
Altor BioScience
Ambit Biosciences
Amgen
Amorfix Life Sciences
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
Apotex
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Ardea Biosciences
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bayer
Benitec
Berkeley Lab
Betapharma
Biocon
BioCryst Pharmaceuticals
Biogen Idec
BioInvent
Biolex
BioLineRx
Bionovo
BioNumerik
BioSante
Biosceptre
Biotecnol
Biotest
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Cancer Advances
Cancer Innovations
Cancer Research Technology
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
Circadian Technologies
CompleGen
Cornerstone Pharmaceuticals
CritiTech
CSL
CuraGen
Curaxis
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
DiaMedica
Dompe
Dr Reddy’s
Dyax
Dynavax Technologies
EGEN Inc
Eisai
Elan
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Ergon Pharmaceuticals
Esperance Pharmaceuticals
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Forma Therapeutics
Fusion Antibodies
Galaxy Biotech
Galectin Therapeutics
GammaCan
Ganymed Pharmaceuticals
Gemin X Biotechnologies
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
Green Cross
Hawthorn Pharmaceuticals
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
IDM Pharma
IGF Oncology
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Inex
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
ISU ABXIS
Italfarmaco
Johnson & Johnson
Kadmon
Kaketsuken
KaloBios
Kinex
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
MAT Biopharma
MBiotec
Meda
Medarex
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mycenax
Nektar Therapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neuren
NIH
Nippon Kayaku
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novogen
Noxxon
Nycomed Pharma
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Onyvax
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanaGin
PanGenetics
Patrys
Pepscan Therapeutics
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacyclics
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
Protgen
Ramot
Ras Therapeutics
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
SBI Biotech
SBIO
Scancell
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Shanghai CP Guojian
Shenogen
Shire
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Switch Pharma
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
Tau Therapeutics
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Titan Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
UMN Pharma
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
VaxOnco
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
ViroMed
Viventia Biotech
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
Zeria
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
adecatumumab
AEG-35156
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
amatuximab
AME-133
AMG-386
amrubicin hydrochloride
apricoxib
ARC-100
ARQ-197
AV-299
bardoxolone methyl
belimumab
belinostat
bevacizumab
bexarotene
BHQ880
blinatumomab
BMS-663513
BMS-936558
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
brivudine
BT-062
Cabozantinib
capecitabine
carlumab
catumaxomab
CDX-1307
CDX-1401
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
cladribine
CMAB302
CMAB304
conatumumab
CPI-613
CRLX-101
CT-011
dalotuzumab
daratumumab
dasatinib
denileukin diftitox
denosumab
docetaxel
doxorubicin
E-7820
elliptinium acetate
elotuzumab
EMD-273063
EMD525797
eniluracil
enzastaurin hydrochloride
epirubicin
epratuzumab
epratuzumab-Y90
erlotinib
ertumaxomab
everolimus
farletuzumab
figitumumab
fresolimumab
galiximab
ganitumab
gefitinib
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
GS-6634
GSK-1120212
GV-1001
GVAX
HBP-347
I-131-labetuzumab
ibritumomab tiuxetan
icotinib hydrochloride
icrucumab
imatinib mesilate
IMP-321
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
intetumumab
IPH-2102
ipilimumab
iratumumab
irinotecan
irinotecan hydrochloride
KD032
L19-IL2
L19-TNFalpha
lapatinib ditosylate
lestaurtinib
lintuzumab
LIP-131I
LipoVIL12
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
masitinib
MCS-110
MEDI-551
MEDI-573
MetXia
milatuzumab
milatuzumab-doxorubicin
mitoxantrone
MKC-1
MM-111
MM-121
mocetinostat
mogamulizumab
MOR202
MOR208
MORAb-004
motexafin gadolinium
moxetumomab pasudotox
nadroparin
naptumomab estafenatox
natalizumab
necitumumab
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaparib
olaratumab
onartuzumab
Onyvax-105
oregovomab
OTS-102
P-276-00
paclitaxel
PancAtak
panitumumab
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
pertuzumab
PF-4856884
pixantrone
plitidepsin
pralatrexate
PX-12
ramucirumab
razoxane
Reditux
Rexin-G
RG-7160
rhIFN-alpha
rilotumumab
rituximab
robatumumab
romidepsin
romiplostim
RX-0201
samalizumab
SAR-3419
selumetinib
siltuximab
sobuzoxane
sorafenib tosylate
sotatercept
ß-lapachone
sunitinib malate
Sym-004
talminogene laherparepvec
tegafur + uracil
temsirolimus
Tenarad
teniposide
tigatuzumab
tocilizumab
trabedersen
trastuzumab
TRC-105
tremelimumab
triciribine phosphate
TRU-016
TS-1
tucotuzumab celmoleukin
U3-1287
Ublituximab
varlitinib
veltuzumab
vismodegib
volociximab
WX-671
yttrium Y 90 clivatuzumab tetraxetan
Z-360
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Pancreatic Cancer and Antibodies.
    To find out more about Triple Analysis: Lymphoma, Pancreatic Cancer and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Pancreatic Cancer and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Lung Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Learn More


Triple Analysis: Lung Cancer, Melanoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the compound strategy of Antibodies. Learn More